Summary Researchers from National Jewish Health have developed and tested a novel method for T lymphocyte immunosuppression. The technology is based on conjugating a CD4 or CD2 molecule with an antibody specific for a cell surface marker. Therefore this technology inhibits CD4+ or CD4+ together with CD8+ T cells, respectively, immune stimulatory cells, without affecting other immune functions.
Advantages of Invention Only lymphocytes that are specific for antigens found on the grafted cells are target, eliminating any broad immunosuppression currently obtained with traditional treatments.
State of Development Technology has been demonstrated in vitro to inhibit CD4+ T cells by conjugating engineered antibody that express CD4 or CD2 molecules onto immune stimulatory cells.
Further R&D Required Demonstrating the efficacy of the technology in vivo.
Licensing Status This technology is available for licensing
For Further Information, Contact: Emmanuel Hilaire, PhD Director Technology Transfer Office National Jewish Health 1400 Jackson Street, Room M206b Denver, CO 80206 Voice: (303) 398-1262 Fax: (303) 270-2352 HilaireE@njhealth.org